Company news

RenovoRx, Inc. news in 2026

RenovoRx, Inc.'s news releases, calls and decks from 2026, newest first.

View company

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

November 5, 2026

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

October 28, 2026

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

October 22, 2026

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

October 7, 2026

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

October 1, 2026

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

September 2, 2026

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

August 25, 2026

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

August 21, 2026

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

August 20, 2026

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

August 12, 2026

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

August 11, 2026

RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

August 7, 2026

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

August 6, 2026

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

August 4, 2026

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4: 30 p.m. ET

July 29, 2026

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

June 11, 2026

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

June 3, 2026

RenovoRx Announces FDA Orphan Drug Designation Granted, Oxaliplatin for the Treatment of Pancreatic Cancer

May 29, 2026

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

May 28, 2026

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

May 26, 2026

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

May 14, 2026

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4: 30 pm ET

April 29, 2026

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

April 23, 2026

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

April 14, 2026

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

April 7, 2026

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

April 1, 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

March 29, 2026

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

March 25, 2026

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

March 22, 2026

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4: 30 p.m. ET

March 20, 2026

RenovoRx Announces $10 Million at Market Private Placement

March 17, 2026

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

February 27, 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

February 26, 2026

RenovoRx Establishes RenovoCath® Medical Advisory Board

February 10, 2026

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

February 5, 2026

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

February 4, 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

January 28, 2026

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

January 20, 2026

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

January 14, 2026

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

January 8, 2026

Calls in 2026

Decks in 2026